A review of new hormonal therapies for prostate cancer in black men: is there enough data? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue BMC Cancer Année : 2021

A review of new hormonal therapies for prostate cancer in black men: is there enough data?

Résumé

Background: Prostate cancer among black men is known to have specific molecular characteristics, especially the androgen receptor or enzymes related to the androgen metabolism. These targets are keys to the action of new hormonal therapies. Nevertheless, literature has a lack of data regarding black men. We aimed to gather the available literature data on new hormonal therapies among black populations.Methods: We conducted a literature review from the PubMed / MEDLINE database until October 2020. All clinical studies of new hormonal therapies and black populations, regardless of methodology, were included.Results: Four studies provided data on new hormonal therapies in black populations. Three studies reported a PSA decline in black patients treated with Abiraterone, higher in black men than in white men. Overall survival also appears to be higher in black patients treated with Abiraterone only or first.Conclusion: Few articles have evaluated the effectiveness and safety of use of these treatments among black populations. The first results seem to show that Abiraterone can provide a benefit in overall survival in black populations. Prospective studies are needed to answer these questions in the future.
Fichier principal
Vignette du fichier
s12885-020-07780-7 (506.74 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03134963 , version 1 (25-05-2021)

Licence

Paternité

Identifiants

Citer

M.E. Meunier, P. Blanchet, Y. Neuzillet, T. Lebret, L. Brureau. A review of new hormonal therapies for prostate cancer in black men: is there enough data?. BMC Cancer, 2021, 21 (1), pp.61. ⟨10.1186/s12885-020-07780-7⟩. ⟨hal-03134963⟩
74 Consultations
25 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More